RecruitingNot ApplicableNCT05711485

Platelet-Directed Whole Blood Transfusion Strategy for Malaria

Clinical and Translational Investigations of Severe Malaria Pathophysiology [Parent Study Protocol]


Sponsor

Johns Hopkins Bloomberg School of Public Health

Enrollment

132 participants

Start Date

Feb 24, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.


Eligibility

Min Age: 6 MonthsMax Age: 59 Months

Inclusion Criteria8

  • Age <5 years
  • Platelet count ≤75,000/uL
  • Hemoglobin >5 and ≤9 g/dL
  • P. falciparum parasitemia ≥500 parasites/uL
  • Diagnosis of severe malaria meeting World Health Organization (WHO) criteria
  • Ability and willingness of the legal guardian to comply with study protocol for the duration of the study
  • Residence within health clinic catchment area
  • Signed informed consent obtained from the parent or legal guardian of the participant

Exclusion Criteria4

  • Residence in foster care or children otherwise under government supervision
  • Residence outside the hospital catchment area, or plan to leave the area
  • Presence of any other condition or abnormality which, in the opinion of the investigator, would compromise the safety of the participant or the quality of the data
  • Any contraindication to whole blood transfusion

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERWhole blood transfusion

Whole blood is sourced from the Zambia National Blood Transfusion Service.


Locations(2)

Johns Hopkins Bloomberg School of Public Health

Baltimore, Maryland, United States

Tropical Diseases Research Centre

Ndola, Copperbelt, Zambia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05711485


Related Trials